GSK May Exit Treximet Spat But Remain On Hook
After pulling GlaxoSmithKline PLC into a patent spat over Pozen Inc.'s migraine treatment Treximet, defendant Par Pharmaceutical Inc. has agreed to drop the British pharmaceutical giant from Pozen's infringement suit in...To view the full article, register now.
Already a subscriber? Click here to view full article